Overexpression of the R2 subunit of ribonucleotide reductase in human nasopharyngeal cancer cells reduces radiosensitivity

Cancer Journal

Volumn 9, Issue 4, 2003, Pages 277-285

  Kuo, Mei Ling ^a   Hwang, Hwa Shin ^a   Sosnay, Patrick R ^a   Kunugi, Keith A ^a   Kinsella, Timothy J ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

G2 delay; Ionizing radiation repair

Indexed keywords

HYDROXYUREA; RIBONUCLEOTIDE REDUCTASE; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; RADIOSENSITIZING AGENT; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M2;

ARTICLE; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME SUBUNIT; HUMAN; HUMAN CELL; IONIZING RADIATION; NASOPHARYNX CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; CARCINOMA; CELL CYCLE; CELL STRAIN KB; DRUG EFFECT; DRUG RESISTANCE; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; IN VITRO STUDY; METABOLISM; NASOPHARYNX TUMOR; RADIATION DOSE; RADIATION EXPOSURE; TUMOR CELL LINE; UPREGULATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARCINOMA; CELL CYCLE; CELL LINE, TUMOR; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXYUREA; KB CELLS; NASOPHARYNGEAL NEOPLASMS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; TRANSFECTION; UP-REGULATION;

EID: 0642368323     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200307000-00010     Document Type: Article

References (46)

1. Kuo ML, Kinsella TJ. Expression of ribonucleotide reductase after ionizing radiation in human cervical carcinoma cells. Cancer Res 1998;58:2245-2252.
2. Zhou BS, Hsu NY, Pan BC et al. Overexpression of ribonucleotide reductase in transfected human KB cells increases their resistance to hydroxyurea: M2 but notM1 is sufficient to increase resistance to hydroxyurea in transfected cells. Cancer Res 1995;55:1328-1333.
3. Reichard P. From RNA to DNA, why so many ribonucleotide reductases? Science 1993;260:1773-1777.
4. Mann GJ, Musgrove EA, Fox RM et al. Ribonucleotide reductase M1 subunit in cellular proliferation, quiescence, and differentiation. Cancer Res 1988;48:5151-5156.
5. Eriksson S, Graslund A, Skog S et al. Cell cycle-dependent regulation of mammalian ribonucleotide reductase: the S phase-correlated increase in subunit M2 is regulated by de novo protein synthesis. J Biol Chem 1984;259:11695-11700.
6. Eriksson S, Martin DWJ. Ribonucleotide reductase in cultured mouse lymphoma cells: cell cycle-dependent variation in the activiity of subunit protein M2. J Biol Chem 1981;256:9436-9440.
7. Engstrom Y, Eriksson S, Jildevik I et al. Cell cycle-dependent expression of mammalian ribonucleotide reductase: differential regulation of the two subunits. J Biol Chem 1985;260:9114-9116.
8. Elledge SJ, Zhou Z, Allen JB. Ribonucleotide reductase: regulation, regulation, regulation. Trends Biochem Sci 1992;17:119-123.
9. Elledge SJ, Zhou Z, Allen JB et al. DNA damage and cell cycle regulation of ribonucleotide reductase. Bioessays 1993;15:333-339.
10. Zhou Z, Elledge SJ. Isolation of crt mutants constitutive for transcription of the DNA damage inducible gene RNR3 in Saccharomyces cerevisiae. Genetics 1992;131:851-866.
11. Elledge SJ, Davis RW. Two genes differentially regulated in the cell cycle and by DNA-damaging agents encode alternative regulatory subunits of ribonucleotide reductase. Genes Dev 1990;4:740-751.
12. Elledge SJ, Davis RW. DNA damage induction of ribonucleotide reductase. Mol Cell Biol 1989;9:4932-4940.
13. Elledge SJ, Davis RW. Identification and isolation of the gene encoding the small subunit of ribonucleotide reductase from Saccharomyces cerevisiae: DNA damage-inducible gene required for mitotic viability. Mol Cell Biol 1987;7:2783-2793.
14. Yagle K, McEntee K. The DNA damage-inducible gene DIN1 of Saccharomyces cerevisiae encodes a regulatory subunit of ribonucleotide reductase and is identical to RNR3. Mol Cell Biol 1990;10:5553-5557.
15. Hurd HK, Roberts JW. Upstream regulatory sequences of the yeast RNR2 gene include a repression sequence and an activation site that binds the RAP1 protein. Mol Cell Biol 1989;9:5359-5372.
16. Hurd HK, Roberts CW, Roberts JW. Identification of the gene for the yeast ribonucleotide reductase small subunit and its inducibility by methyl methanesulfonate. Mol Cell Biol 1987;7:3673-3677.
17. Hurta RA, Wright JA. Alterations in the activity and regulation of mammalian ribonucleotide reductase by chlorambucil, a DNA damaging agent. J Biol Chem 1992;267:7066-7071.
18. Filatov D, Bjorklund S, Johansson E et al. Induction of the mouse ribonucleotide reductase R1 and R2 genes in response to DNA damage by UV light. J Biol Chem 1996;271:23698-23704.
19. Lassmann G, Thelander L, Graslund A. EPR stopped-flow studies of the reaction of the tyrosyl radical of protein R2 from ribonucleotide reductase with hydroxyurea. Biochem Biophys Res Commun 1992;188:879-887.
20. Bianchi V, Pontis E, Reichard P. Changes of deoxyribonucleoside triphosphate pools induced by hydroxyurea and their relation to DNA synthesis. J Biol Chem 1986;261:16037-16042.
21. Bianchi V, Pontis E, Reichard P. Interrelations between substrate cycles and de novo synthesis of pyrimidine deoxyribonucleoside triphosphates in 3T6 cells. Proc Natl Acad Sci USA 1986;83:986-990.
22. Collins A, Oates DJ. Hydroxyurea: effects on deoxyribonucleotide pool sizes correlated with effects on DNA repair in mammalian cells. Eur J Biochem 1987;169:299-305.
23. Skoog L, Nordenskjold B. Effects of hydroxyurea and 1-beta-D-arabinofuranosyl-cytosine on deoxyribonucleotide pools in mouse embryo cells. Eur J Biochem 1971;19:81-89.
24. Snyder RD. Deoxyribonucleoside triphosphate pools in human diploid fibroblasts and their modulation by hydroxyurea and deoxynucleosides. Biochem Pharmacol 1984;33:1515-1518.
25. Snyder RD. The role of deoxynucleoside triphosphate pools in the inhibition of DNA-excision repair and replication in human cells by hydroxyurea. Mutat Res 1984;131:163-172.
26. Kuo ML, Kunugi KA, Lindstrom MJ et al. The interaction of hydroxyurea and ionizing radiation in human cervical carcinoma cells. Cancer J Sci Am 1997;3:163-173.
27. Sinclair WK. The combined effect of hydroxyurea and x-rays on Chinese hamster cells in vitro. Cancer Res 1968;28:198-206.
28. Piver MS, Howes AE, Suit HD et al. Effect of hydroxyurea on the radiation response of C3H mousemammary tumors. Cancer 1972;29:407-412.
29. Stehman FB, Bundy BN, Thomas G et al. Hydroxyurea versus misonidazole with radiation in cervical carcinoma: long-term follow-up of a Gynecologic Oncology Group trial. J Clin Oncol 1993;11:1523-1528.
30. Whitney CW, Sause W, Bundy BN et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999;17:1339-1348.
31. Beitler JJ, Anderson P, Haynes H et al. Phase I clinical trial of parenteral hydroxyurea in combination with pelvic and para-aortic external radiation and brachytherapy for patients with advanced squamous cell cancer of the uterine cervix. Int J Radiat Oncol Biol Phys 2002;52:637-642.
32. Vokes EE, Panje WR, Schilsky RL et al. Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study. J Clin Oncol 1989;7:761-768.
33. Mantz CA, Vokes EE, Stenson K et al. Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced oropharyngeal cancer. Cancer J 2001;7:140-148.
34. Kuo ML, Kinsella TJ. Overexpression of a hexa-histidine and T7 peptide-tagged human ribonucleotide reductase small subunit, R2 in Escherichia coli and the generation of human R2 antibodies. Int J Oncol 1997;10:515-520.
35. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
36. Lindstrom MJ, Kunugi KA, Kinsella TJ. Global comparison of radiation and chemotherapy dose-response curves with a test for interaction. Radiat Res 1993;135:269-277.
37. Kunugi KA, Lindstrom MJ, Kinsella TJ. Effects of bleomycin with iododeoxyuridine, 5′-amino-5′-deoxythymidine, and radiation in a human bladder cancer cell line. Radiat Res 1993;135:262-268.
38. Tanaka H, Arakawa H, Yamaguchi T et al. A ribonucleotide reduc-tase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 2000;404:42-49.
39. Nakano K, Balint E, Ashcroft M et al. A ribonucleotide reductase gene is a transcriptional target of p53 and p73. Oncogene 2000;19:4283-4289.
40. Guittet O, Hakansson P, Voevodskaya N et al. Mammalian p53R2 protein forms an active ribonucleotide reductase in vitro with the R1 protein, which is expressed both in resting cells in response to DNA damage and in proliferating cells. J Biol Chem 2001;276:40647-40651.
41. Yamaguchi T, Matsuda K, SagiyaY et al. p53R2-dependent pathway forDNA synthesis in a p53-regulated cell cycle checkpoint. Cancer Res 2001;61:8256-8262.
42. Thompson DP, Carter GL, Cory JG. Changes in messenger RNA levels for the subunits of ribonucleotide reductase during the cell cycle of leukemia L1210 cells. Cancer Commun 1989;1:253-260.
43. Albert DA, Nodzenski E, Yim G et al. Effect of cyclic AMP on the cell cycle regulation of ribonucleotide reductase M2 subunit messenger RNA concentrations in wild-type and mutant S49 T lymphoma cells. J Cell Physiol 1990;143:251-256.
44. Feder JN, Guidos CJ, Kusler B et al. A cell cycle analysis of growt-related genes expressed during T lymphocyte maturation. J Cell Biol 1990;111:2693-2701.
45. Albert DA, Rozengurt E. Synergistic and coordinate expression of the genes encoding ribonucleotide reductase subunits in Swiss 3T3 cells: effect of multiple signal-transduction pathways. Proc Natl Acad Sci USA 1992;89:1597-1601.
46. Orr RM. GTI-2040. Lorus Therapeutics. Current Opin Invest Drugs 2:1462-1466.